Home / Recalls / STAQ Pharma, Inc. / D-0023-2026

D-0023-2026 Class III Ongoing

Recalled by STAQ Pharma, Inc. — Denver, CO

FDA drug recall D-0023-2026 was initiated by STAQ Pharma, Inc. on October 9, 2025 and is designated Class III. Reason for recall: Labeling: Incorrect or Missing Lot and/or Exp Date The recall status is ongoing.

Recall Details

Product Type: Drugs
Report Date: October 22, 2025
Initiation Date: October 9, 2025
Termination Date: N/A
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity

Product Description

Hydromorphone HCL PF, 10mg/50 mL (0.2mg/mL) in NACL, Injection for IV use, 50 mL Syringe, STAQ Pharma Inc., 14135 E 42nd Ave, Denver, Colorado, NDC 73177-0104-05.

Reason for Recall

Labeling: Incorrect or Missing Lot and/or Exp Date

Distribution Pattern

Nationwide in the U.S.

Code Information

Lot #: 25104595A, Expiry: 27DEC2025.

Other recalls by STAQ Pharma, Inc.

D-0024-2026 Class III — Ketamine Hydrochloride, 50mg/5 mL (10mg/mL), Injection for IV use, 50 mL syringe (October 9, 2025)
D-0025-2026 Class III — FentaNYL Citrate PF, 500mcg/50 mL (10mcg/mL) in NACL, Injection for IV use, 50 m (October 9, 2025)
D-0147-2024 Class II — ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/500 mL (2 mg per mL) Injecti (November 29, 2023)
D-0633-2022 Class I — HYDROmorphone HCl PF 10 mg/50 mL (0.2mg/mL) in NaCl, 50 mL in 50 mL Single Dose (February 3, 2022)
D-0634-2022 Class I — Morphine Sulfate PF 25 mg/25mL (1 mg/mL) in NaCl, 25 mL in 30 mL Single Dose Syr (February 3, 2022)